Literature DB >> 10490269

Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II).

T Sasada1, H Nakamura, S Ueda, N Sato, Y Kitaoka, Y Gon, A Takabayashi, G Spyrou, A Holmgren, J Yodoi.   

Abstract

The thioredoxin (TRX) system, composed of nicotinamide adenine dinucleotide phosphate (reduced form), TRX, and TRX reductase (TRXR), has multiple biologic functions via thiol-mediated redox control. In this study, we investigated the relationship between intracellular TRXR levels and cellular sensitivity to cis-diamminedichloroplatinum (II) (CDDP). HeLa, a human cervical carcinoma cell line, cultured with CDDP showed a time- and dose-dependent reduction of intracellular TRXR activity, which was well correlated with the decrease in cell viability after exposure to CDDP. In a cell-free system, CDDP was found to directly inactivate the reduced form of purified human TRXR. The CDDP-resistant variants of HeLa cells, established by continuous exposure to CDDP, exhibited an increased expression and activity of TRXR as well as TRX compared with the parental cells. In addition, sodium selenate, an inhibitor of TRXR, was found to increase the susceptibility to CDDP in the CDDP-resistant cells. Moreover, the HeLa cells transfected with an antisense TRXR RNA expression vector to reduce the intracellular enzyme activity displayed an enhanced sensitivity to CDDP. Taken together with previous reports on TRX, these results indicate the possible involvement of TRXR as well as TRX in the cellular sensitivity and resistance to CDDP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490269     DOI: 10.1016/s0891-5849(99)00101-x

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  29 in total

1.  Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction.

Authors:  Robyn L Poerschke; Philip J Moos
Journal:  Biochem Pharmacol       Date:  2010-10-12       Impact factor: 5.858

2.  Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay.

Authors:  Stefanie Prast-Nielsen; Thomas S Dexheimer; Lena Schultz; William C Stafford; Qing Cheng; Jianqiang Xu; Ajit Jadhav; Elias S J Arnér; Anton Simeonov
Journal:  Free Radic Biol Med       Date:  2011-01-22       Impact factor: 7.376

3.  The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells.

Authors:  Medhi Wangpaichitr; Elizabeth J Sullivan; George Theodoropoulos; Chunjing Wu; Min You; Lynn G Feun; Theodore J Lampidis; Macus T Kuo; Niramol Savaraj
Journal:  Mol Cancer Ther       Date:  2012-01-16       Impact factor: 6.261

4.  Hepatocytes lacking thioredoxin reductase 1 have normal replicative potential during development and regeneration.

Authors:  MaryClare F Rollins; Dana M van der Heide; Carla M Weisend; Jean A Kundert; Kristin M Comstock; Elena S Suvorova; Mario R Capecchi; Gary F Merrill; Edward E Schmidt
Journal:  J Cell Sci       Date:  2010-06-22       Impact factor: 5.285

5.  Glutathione and glutaredoxin act as a backup of human thioredoxin reductase 1 to reduce thioredoxin 1 preventing cell death by aurothioglucose.

Authors:  Yatao Du; Huihui Zhang; Jun Lu; Arne Holmgren
Journal:  J Biol Chem       Date:  2012-09-13       Impact factor: 5.157

6.  Reactive aldehyde modification of thioredoxin-1 activates early steps of inflammation and cell adhesion.

Authors:  Young-Mi Go; Patrick J Halvey; Jason M Hansen; Matt Reed; Jan Pohl; Dean P Jones
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

7.  Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and -resistant human ovarian cancer cells.

Authors:  Gaetano Marverti; Alessio Ligabue; Monica Montanari; Davide Guerrieri; Matteo Cusumano; Maria Letizia Di Pietro; Leonarda Troiano; Elena Di Vono; Stefano Iotti; Giovanna Farruggia; Federica Wolf; Maria Giuseppina Monti; Chiara Frassineti
Journal:  Invest New Drugs       Date:  2009-10-16       Impact factor: 3.850

8.  N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS).

Authors:  Medhi Wangpaichitr; Chunjing Wu; Min You; Johnathan C Maher; Vy Dinh; Lynn G Feun; Niramol Savaraj
Journal:  Cancers (Basel)       Date:  2009       Impact factor: 6.639

9.  Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo.

Authors:  Qiang Tan; Jing Li; Han-wei Yin; Li-hui Wang; Wan-chen Tang; Fang Zhao; Xin-min Liu; Hui-hui Zeng
Journal:  Invest New Drugs       Date:  2009-03-07       Impact factor: 3.850

10.  Stereochemical configuration of 4-hydroxy-2-nonenal-cysteine adducts and their stereoselective formation in a redox-regulated protein.

Authors:  Chika Wakita; Takuya Maeshima; Atsushi Yamazaki; Takahiro Shibata; Sohei Ito; Mitsugu Akagawa; Makoto Ojika; Junji Yodoi; Koji Uchida
Journal:  J Biol Chem       Date:  2009-08-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.